AAAAAA

   
Results: 1-16 |
Results: 16
Aging-related growth hormone (GH) decrease is a selective hypothalamic GH-releasing hormone pulse amplitude mediated phenomenon
Authors: Russell-Aulet, M Dimaraki, EV Jaffe, CA DeMott-Friberg, R Barkan, AL
Citation: M. Russell-aulet et al., Aging-related growth hormone (GH) decrease is a selective hypothalamic GH-releasing hormone pulse amplitude mediated phenomenon, J GERONT A, 56(2), 2001, pp. M124-M129
State-of-the-art strategies for the diagnosis and management of acromegaly
Authors: Klibanski, A Ho, K Freda, PU Clemmons, DR Barkan, AL Kleinberg, DL Trainer, PJ Swearingen, B Molitch, ME Wass, JAH Thorner, MO Melmed, S Strasburger, CJ Frohman, LA
Citation: A. Klibanski et al., State-of-the-art strategies for the diagnosis and management of acromegaly, ENDOCRINOLO, 11(3), 2001, pp. 223-232
Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator
Authors: Dimaraki, EV Jaffe, CA Demott-Friberg, R Russell-Aulet, M Bowers, CY Marbach, P Barkan, AL
Citation: Ev. Dimaraki et al., Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator, AM J P-ENDO, 280(3), 2001, pp. E489-E495
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
Authors: van der Lely, AJ Hutson, RK Trainer, PJ Besser, GM Barkan, AL Katznelson, L Klibanski, A Herman-Bonert, V Melmed, S Vance, ML Freda, PU Stewart, PM Friend, KE Clemmons, DR Johannsson, G Stavrou, S Cook, DM Phillips, LS Strasburger, CJ Hacker, S Zib, KA Davis, RJ Scarlett, JA Thorner, M
Citation: Aj. Van Der Lely et al., Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, LANCET, 358(9295), 2001, pp. 1754-1759
Regulation of GH secretion in acromegaly: Reproducibility of daily GH profiles and attenuated negative feedback by IGF-I
Authors: Jaffe, CA Pan, WQ Brown, MB DeMott-Friberg, R Barkan, AL
Citation: Ca. Jaffe et al., Regulation of GH secretion in acromegaly: Reproducibility of daily GH profiles and attenuated negative feedback by IGF-I, J CLIN END, 86(9), 2001, pp. 4364-4370
The "quality of life-assessment of growth hormone deficiency in adults" questionnaire: Can it be used to assess quality of life in hypopituitarism?"
Authors: Barkan, AL
Citation: Al. Barkan, The "quality of life-assessment of growth hormone deficiency in adults" questionnaire: Can it be used to assess quality of life in hypopituitarism?", J CLIN END, 86(5), 2001, pp. 1905-1907
Semiquantification of hypothalamic GH-releasing hormone output in women: Evidence for sexual dimorphism in the mechanism of the somatopause
Authors: Orrego, JJ Russell-Aulet, M Demott-Friberg, R Barkan, AL
Citation: Jj. Orrego et al., Semiquantification of hypothalamic GH-releasing hormone output in women: Evidence for sexual dimorphism in the mechanism of the somatopause, J CLIN END, 86(11), 2001, pp. 5485-5490
Growth hormone therapy for hypopituitary adults: Time for re-appraisal
Authors: Barkan, AL Clemmons, DR Molitch, ME Stewart, PM Young, WF
Citation: Al. Barkan et al., Growth hormone therapy for hypopituitary adults: Time for re-appraisal, TRENDS ENDO, 11(6), 2000, pp. 238-245
Growth hormone secretory dynamics over the menstrual cycle
Authors: Jaffe, CA Ocampo-Lim, B Guo, WS Krueger, K Sugahara, I Demott-Friberg, R Barkan, AL
Citation: Ca. Jaffe et al., Growth hormone secretory dynamics over the menstrual cycle, ENDOCR J, 47(5), 2000, pp. 549-556
Induction of growth hormone (GH) mRNA by pulsatile GH-releasing hormone inrats is pattern specific
Authors: Borski, RJ Tsai, W Demott-Friberg, R Barkan, AL
Citation: Rj. Borski et al., Induction of growth hormone (GH) mRNA by pulsatile GH-releasing hormone inrats is pattern specific, AM J P-ENDO, 278(5), 2000, pp. E885-E891
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
Authors: Trainer, PJ Drake, WM Katznelson, L Freda, PU Herman-Bonert, V van der Lely, AJ Dimaraki, EV Stewart, PM Friend, KE Vance, ML Besser, GM Scarlett, JA Thorner, MO Parkinson, C Klibanski, A Powell, JS Barkan, AL Sheppard, MC Maldonado, M Rose, DR Clemmons, DR Johannson, G Bengtsson, BA Stavrou, S Kleinberg, DL Cook, DM Phillips, LS Bidlingmaier, M Strasburger, CJ Hackett, S Zib, K Bennett, WF Davis, RJ
Citation: Pj. Trainer et al., Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N ENG J MED, 342(16), 2000, pp. 1171-1177
Pituitary disorders - Drug treatment options
Authors: Orrego, JJ Barkan, AL
Citation: Jj. Orrego et Al. Barkan, Pituitary disorders - Drug treatment options, DRUGS, 59(1), 2000, pp. 93-106
Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma
Authors: Meyer, P Bohnen, NI Barkan, AL Shapiro, B
Citation: P. Meyer et al., Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma, NUKLEARMED, 38(2), 1999, pp. 66-67
Kallman's syndrome: is it always for life?
Authors: Barkan, AL
Citation: Al. Barkan, Kallman's syndrome: is it always for life?, CLIN ENDOCR, 51(6), 1999, pp. 817-818
In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: Evidence for relative GHRH deficiency in aging
Authors: Russell-Aulet, M Jaffe, CA Demott-Friberg, R Barkan, AL
Citation: M. Russell-aulet et al., In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: Evidence for relative GHRH deficiency in aging, J CLIN END, 84(10), 1999, pp. 3490-3497
Chromosome 13q deletion mapping in pituitary tumors: Infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas
Authors: Simpson, DJ Magnay, J Bicknell, JE Barkan, AL McNicol, AM Clayton, RN Farrell, WE
Citation: Dj. Simpson et al., Chromosome 13q deletion mapping in pituitary tumors: Infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite loss of RB1 protein product in somatotrophinomas, CANCER RES, 59(7), 1999, pp. 1562-1566
Risultati: 1-16 |